Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback